Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 20.43 kDa 
• Atom Count: 1457 
• Residue Count: 157 
• Unique protein chains: 1

3SRW

S. aureus Dihydrofolate Reductase complexed with novel 7-aryl-2,4-diaminoquinazolines

• DOI: 10.2210/pdb3SRW/pdb

• Classification: OXIDOREDUCTASE/OXIDOREDUCTASE INHIBITOR
• Organism(s): Staphylococcus aureus
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2011-07-07 Released: 2011-08-31 
• Deposition Author(s): Hilgers, M.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.70 Å
• R-Value Free: 0.222 
• R-Value Work: 0.192 
• R-Value Observed: 0.194 

Literature

Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines.

Li, X., Hilgers, M., Cunningham, M., Chen, Z., Trzoss, M., Zhang, J., Kohnen, L., Lam, T., Creighton, C., G C, K., Nelson, K., Kwan, B., Stidham, M., Brown-Driver, V., Shaw, K.J., Finn, J.

(2011) Bioorg Med Chem Lett 21: 5171-5176

• PubMed: 21831637 
• DOI: 10.1016/j.bmcl.2011.07.059
• Primary Citation of Related Structures:  
  3SRQ, 3SQY, 3SR5, 3SRR, 3SRS, 3SRU, 3SRW


• PubMed Abstract: 
  

Dihydrofolate reductase (DHFR) inhibitors such as trimethoprim (TMP) have long played a significant role in the treatment of bacterial infections. Not surprisingly, after decades of use there is now bacterial resistance to TMP and therefore a need to develop novel antibacterial agents with expanded spectrum including these resistant strains. In this study, we investigated the optimization of 2,4-diamnoquinazolines for antibacterial potency and selectivity. Using structure-based drug design, several 7-aryl-2,4-diaminoquinazolines were discovered that have excellent sub-100 picomolar potency against bacterial DHFR. These compounds have good antibacterial activity especially on gram-positive pathogens including TMP-resistant strains.

---

Organizational Affiliation: 

Trius Therapeutics, San Diego, CA 92121, United States.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Dihydrofolate reductase	X	167	Staphylococcus aureus	Mutation(s): 0  Gene Names: folA EC: 1.5.1.3
Find proteins for P0A017 (Staphylococcus aureus) Explore P0A017  Go to UniProtKB:  P0A017

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
NAP	X	NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE C21 H28 N7 O17 P3 XJLXINKUBYWONI-NNYOXOHSSA-N
Q27	X	7-(2-ethoxynaphthalen-1-yl)-6-methylquinazoline-2,4-diamine C21 H20 N4 O DYQBRXOQGFCHCN-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
Q27	Ki:  0.026000000536441803   nM  Binding MOAD
Q27	Ki:  0.029999999329447746   nM  BindingDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.70 Å
• R-Value Free: 0.222 
• R-Value Work: 0.192 
• R-Value Observed: 0.194 
• Space Group: P 6₁ 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 79.287	α = 90
b = 79.287	β = 90
c = 107.354	γ = 120

Software Package:

Software Name	Purpose
MOSFLM	data reduction
SCALA	data scaling
PHASER	phasing
REFMAC	refinement
PDB_EXTRACT	data extraction

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2011-07-07 
• Released Date: 2011-08-31 
Deposition Author(s): Hilgers, M.

Revision History 

• Version 1.0: 2011-08-31
  Type: Initial release
  
• Version 1.1: 2011-10-19
  Changes: Database references